NasdaqGS:TWSTBiotechs
Should Twist Bioscience’s US$17.05 Million Class Action Settlement Reshape Risk Perceptions for TWST Investors?
Twist Bioscience Corporation recently held a hearing on a proposed US$17,050,000 cash settlement to resolve a securities class action covering purchasers of its common stock between December 20, 2018 and November 15, 2022, as well as participants in its December 2020 offering.
The proposed settlement, if fully approved, would close off ongoing litigation risk for a large group of past investors and clarify Twist Bioscience’s legal exposure tied to earlier capital-raising activities.
We’ll...